nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Carmustine—lymphatic system cancer	0.125	1	CbGbCtD
Rasagiline—Eye disorder—Carmustine—lymphatic system cancer	0.00101	0.00116	CcSEcCtD
Rasagiline—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00101	0.00116	CcSEcCtD
Rasagiline—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00101	0.00116	CcSEcCtD
Rasagiline—Hypersensitivity—Teniposide—lymphatic system cancer	0.00101	0.00115	CcSEcCtD
Rasagiline—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00101	0.00115	CcSEcCtD
Rasagiline—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.001	0.00115	CcSEcCtD
Rasagiline—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.001	0.00114	CcSEcCtD
Rasagiline—Anaemia—Bleomycin—lymphatic system cancer	0.001	0.00114	CcSEcCtD
Rasagiline—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000992	0.00113	CcSEcCtD
Rasagiline—Asthenia—Teniposide—lymphatic system cancer	0.000983	0.00112	CcSEcCtD
Rasagiline—Melaena—Methotrexate—lymphatic system cancer	0.000977	0.00112	CcSEcCtD
Rasagiline—Malaise—Bleomycin—lymphatic system cancer	0.000976	0.00112	CcSEcCtD
Rasagiline—Pruritus—Teniposide—lymphatic system cancer	0.000969	0.00111	CcSEcCtD
Rasagiline—Leukopenia—Bleomycin—lymphatic system cancer	0.000968	0.00111	CcSEcCtD
Rasagiline—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000966	0.0011	CcSEcCtD
Rasagiline—Cardiac disorder—Vincristine—lymphatic system cancer	0.000961	0.0011	CcSEcCtD
Rasagiline—Alopecia—Carmustine—lymphatic system cancer	0.000959	0.0011	CcSEcCtD
Rasagiline—Body temperature increased—Fludarabine—lymphatic system cancer	0.000952	0.00109	CcSEcCtD
Rasagiline—Mental disorder—Carmustine—lymphatic system cancer	0.00095	0.00109	CcSEcCtD
Rasagiline—Vaginal infection—Methotrexate—lymphatic system cancer	0.000945	0.00108	CcSEcCtD
Rasagiline—Malnutrition—Carmustine—lymphatic system cancer	0.000944	0.00108	CcSEcCtD
Rasagiline—Cough—Bleomycin—lymphatic system cancer	0.000944	0.00108	CcSEcCtD
Rasagiline—Angiopathy—Vincristine—lymphatic system cancer	0.000939	0.00107	CcSEcCtD
Rasagiline—Diarrhoea—Teniposide—lymphatic system cancer	0.000937	0.00107	CcSEcCtD
Rasagiline—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000933	0.00107	CcSEcCtD
Rasagiline—Chest pain—Bleomycin—lymphatic system cancer	0.000921	0.00105	CcSEcCtD
Rasagiline—Alopecia—Vincristine—lymphatic system cancer	0.000915	0.00105	CcSEcCtD
Rasagiline—Back pain—Carmustine—lymphatic system cancer	0.000913	0.00104	CcSEcCtD
Rasagiline—Discomfort—Bleomycin—lymphatic system cancer	0.00091	0.00104	CcSEcCtD
Rasagiline—Mental disorder—Vincristine—lymphatic system cancer	0.000907	0.00104	CcSEcCtD
Rasagiline—Chills—Mitoxantrone—lymphatic system cancer	0.000905	0.00103	CcSEcCtD
Rasagiline—Neoplasm—Methotrexate—lymphatic system cancer	0.000905	0.00103	CcSEcCtD
Rasagiline—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000905	0.00103	CcSEcCtD
Rasagiline—Ecchymosis—Methotrexate—lymphatic system cancer	0.000905	0.00103	CcSEcCtD
Rasagiline—Urine output increased—Methotrexate—lymphatic system cancer	0.000905	0.00103	CcSEcCtD
Rasagiline—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000895	0.00102	CcSEcCtD
Rasagiline—Alopecia—Mitoxantrone—lymphatic system cancer	0.000891	0.00102	CcSEcCtD
Rasagiline—Confusional state—Bleomycin—lymphatic system cancer	0.00089	0.00102	CcSEcCtD
Rasagiline—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000887	0.00101	CcSEcCtD
Rasagiline—Tremor—Carmustine—lymphatic system cancer	0.000885	0.00101	CcSEcCtD
Rasagiline—Infection—Bleomycin—lymphatic system cancer	0.000877	0.001	CcSEcCtD
Rasagiline—Anaemia—Carmustine—lymphatic system cancer	0.000873	0.000998	CcSEcCtD
Rasagiline—Back pain—Vincristine—lymphatic system cancer	0.000872	0.000997	CcSEcCtD
Rasagiline—Vomiting—Teniposide—lymphatic system cancer	0.000871	0.000996	CcSEcCtD
Rasagiline—Agitation—Carmustine—lymphatic system cancer	0.000868	0.000992	CcSEcCtD
Rasagiline—Asthenia—Fludarabine—lymphatic system cancer	0.000864	0.000988	CcSEcCtD
Rasagiline—Rash—Teniposide—lymphatic system cancer	0.000864	0.000988	CcSEcCtD
Rasagiline—Dermatitis—Teniposide—lymphatic system cancer	0.000863	0.000987	CcSEcCtD
Rasagiline—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00086	0.000983	CcSEcCtD
Rasagiline—Headache—Teniposide—lymphatic system cancer	0.000858	0.000981	CcSEcCtD
Rasagiline—Pruritus—Fludarabine—lymphatic system cancer	0.000852	0.000974	CcSEcCtD
Rasagiline—Back pain—Mitoxantrone—lymphatic system cancer	0.000849	0.000971	CcSEcCtD
Rasagiline—Leukopenia—Carmustine—lymphatic system cancer	0.000845	0.000966	CcSEcCtD
Rasagiline—Anorexia—Bleomycin—lymphatic system cancer	0.000842	0.000962	CcSEcCtD
Rasagiline—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000839	0.000959	CcSEcCtD
Rasagiline—Anaemia—Vincristine—lymphatic system cancer	0.000833	0.000952	CcSEcCtD
Rasagiline—Agitation—Vincristine—lymphatic system cancer	0.000828	0.000947	CcSEcCtD
Rasagiline—Polyuria—Methotrexate—lymphatic system cancer	0.000827	0.000946	CcSEcCtD
Rasagiline—Hypotension—Bleomycin—lymphatic system cancer	0.000825	0.000943	CcSEcCtD
Rasagiline—Diarrhoea—Fludarabine—lymphatic system cancer	0.000824	0.000942	CcSEcCtD
Rasagiline—Convulsion—Carmustine—lymphatic system cancer	0.000818	0.000935	CcSEcCtD
Rasagiline—Hypertension—Carmustine—lymphatic system cancer	0.000815	0.000932	CcSEcCtD
Rasagiline—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000815	0.000931	CcSEcCtD
Rasagiline—Nausea—Teniposide—lymphatic system cancer	0.000814	0.00093	CcSEcCtD
Rasagiline—Anaemia—Mitoxantrone—lymphatic system cancer	0.000811	0.000928	CcSEcCtD
Rasagiline—Vertigo—Vincristine—lymphatic system cancer	0.00081	0.000926	CcSEcCtD
Rasagiline—Leukopenia—Vincristine—lymphatic system cancer	0.000807	0.000922	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000804	0.00092	CcSEcCtD
Rasagiline—Chest pain—Carmustine—lymphatic system cancer	0.000804	0.000919	CcSEcCtD
Rasagiline—Anxiety—Carmustine—lymphatic system cancer	0.000801	0.000916	CcSEcCtD
Rasagiline—Paraesthesia—Bleomycin—lymphatic system cancer	0.000793	0.000906	CcSEcCtD
Rasagiline—Malaise—Mitoxantrone—lymphatic system cancer	0.000792	0.000905	CcSEcCtD
Rasagiline—Dyspnoea—Bleomycin—lymphatic system cancer	0.000787	0.0009	CcSEcCtD
Rasagiline—Renal failure acute—Methotrexate—lymphatic system cancer	0.000787	0.000899	CcSEcCtD
Rasagiline—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000786	0.000898	CcSEcCtD
Rasagiline—Convulsion—Vincristine—lymphatic system cancer	0.000781	0.000893	CcSEcCtD
Rasagiline—Hypertension—Vincristine—lymphatic system cancer	0.000778	0.00089	CcSEcCtD
Rasagiline—Confusional state—Carmustine—lymphatic system cancer	0.000777	0.000888	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00077	0.00088	CcSEcCtD
Rasagiline—Decreased appetite—Bleomycin—lymphatic system cancer	0.000767	0.000877	CcSEcCtD
Rasagiline—Cough—Mitoxantrone—lymphatic system cancer	0.000766	0.000876	CcSEcCtD
Rasagiline—Infection—Carmustine—lymphatic system cancer	0.000766	0.000875	CcSEcCtD
Rasagiline—Vomiting—Fludarabine—lymphatic system cancer	0.000766	0.000875	CcSEcCtD
Rasagiline—Convulsion—Mitoxantrone—lymphatic system cancer	0.000761	0.00087	CcSEcCtD
Rasagiline—Rash—Fludarabine—lymphatic system cancer	0.000759	0.000868	CcSEcCtD
Rasagiline—Dermatitis—Fludarabine—lymphatic system cancer	0.000759	0.000867	CcSEcCtD
Rasagiline—Hypertension—Mitoxantrone—lymphatic system cancer	0.000758	0.000866	CcSEcCtD
Rasagiline—Headache—Fludarabine—lymphatic system cancer	0.000754	0.000862	CcSEcCtD
Rasagiline—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000747	0.000854	CcSEcCtD
Rasagiline—Chest pain—Mitoxantrone—lymphatic system cancer	0.000747	0.000854	CcSEcCtD
Rasagiline—Anxiety—Mitoxantrone—lymphatic system cancer	0.000745	0.000851	CcSEcCtD
Rasagiline—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000741	0.000847	CcSEcCtD
Rasagiline—Discomfort—Mitoxantrone—lymphatic system cancer	0.000738	0.000844	CcSEcCtD
Rasagiline—Anorexia—Carmustine—lymphatic system cancer	0.000735	0.00084	CcSEcCtD
Rasagiline—Infection—Vincristine—lymphatic system cancer	0.000731	0.000836	CcSEcCtD
Rasagiline—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000728	0.000832	CcSEcCtD
Rasagiline—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000726	0.00083	CcSEcCtD
Rasagiline—Confusional state—Mitoxantrone—lymphatic system cancer	0.000722	0.000826	CcSEcCtD
Rasagiline—Nervous system disorder—Vincristine—lymphatic system cancer	0.000721	0.000825	CcSEcCtD
Rasagiline—Hypotension—Carmustine—lymphatic system cancer	0.00072	0.000823	CcSEcCtD
Rasagiline—Nausea—Fludarabine—lymphatic system cancer	0.000715	0.000818	CcSEcCtD
Rasagiline—Infection—Mitoxantrone—lymphatic system cancer	0.000712	0.000814	CcSEcCtD
Rasagiline—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000711	0.000813	CcSEcCtD
Rasagiline—Shock—Mitoxantrone—lymphatic system cancer	0.000705	0.000806	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000702	0.000803	CcSEcCtD
Rasagiline—Urticaria—Bleomycin—lymphatic system cancer	0.000701	0.000802	CcSEcCtD
Rasagiline—Anorexia—Vincristine—lymphatic system cancer	0.000701	0.000802	CcSEcCtD
Rasagiline—Body temperature increased—Bleomycin—lymphatic system cancer	0.000698	0.000798	CcSEcCtD
Rasagiline—Insomnia—Carmustine—lymphatic system cancer	0.000697	0.000797	CcSEcCtD
Rasagiline—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000696	0.000796	CcSEcCtD
Rasagiline—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000693	0.000792	CcSEcCtD
Rasagiline—Paraesthesia—Carmustine—lymphatic system cancer	0.000692	0.000791	CcSEcCtD
Rasagiline—Mood swings—Methotrexate—lymphatic system cancer	0.000688	0.000787	CcSEcCtD
Rasagiline—Hypotension—Vincristine—lymphatic system cancer	0.000687	0.000786	CcSEcCtD
Rasagiline—Dyspnoea—Carmustine—lymphatic system cancer	0.000687	0.000785	CcSEcCtD
Rasagiline—Somnolence—Carmustine—lymphatic system cancer	0.000685	0.000783	CcSEcCtD
Rasagiline—Anorexia—Mitoxantrone—lymphatic system cancer	0.000683	0.000781	CcSEcCtD
Rasagiline—Ataxia—Methotrexate—lymphatic system cancer	0.000683	0.000781	CcSEcCtD
Rasagiline—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000671	0.000767	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00067	0.000766	CcSEcCtD
Rasagiline—Decreased appetite—Carmustine—lymphatic system cancer	0.00067	0.000766	CcSEcCtD
Rasagiline—Hypotension—Mitoxantrone—lymphatic system cancer	0.000669	0.000765	CcSEcCtD
Rasagiline—Insomnia—Vincristine—lymphatic system cancer	0.000665	0.000761	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000665	0.000761	CcSEcCtD
Rasagiline—Paraesthesia—Vincristine—lymphatic system cancer	0.000661	0.000755	CcSEcCtD
Rasagiline—Constipation—Carmustine—lymphatic system cancer	0.000659	0.000753	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000653	0.000746	CcSEcCtD
Rasagiline—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00065	0.000744	CcSEcCtD
Rasagiline—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000643	0.000735	CcSEcCtD
Rasagiline—Decreased appetite—Vincristine—lymphatic system cancer	0.00064	0.000731	CcSEcCtD
Rasagiline—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000639	0.00073	CcSEcCtD
Rasagiline—Somnolence—Mitoxantrone—lymphatic system cancer	0.000637	0.000728	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000635	0.000726	CcSEcCtD
Rasagiline—Feeling abnormal—Carmustine—lymphatic system cancer	0.000635	0.000726	CcSEcCtD
Rasagiline—Asthenia—Bleomycin—lymphatic system cancer	0.000633	0.000724	CcSEcCtD
Rasagiline—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000631	0.000721	CcSEcCtD
Rasagiline—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00063	0.00072	CcSEcCtD
Rasagiline—Constipation—Vincristine—lymphatic system cancer	0.000629	0.000719	CcSEcCtD
Rasagiline—Asthma—Methotrexate—lymphatic system cancer	0.000628	0.000718	CcSEcCtD
Rasagiline—Pruritus—Bleomycin—lymphatic system cancer	0.000625	0.000714	CcSEcCtD
Rasagiline—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000623	0.000712	CcSEcCtD
Rasagiline—Constipation—Mitoxantrone—lymphatic system cancer	0.000613	0.0007	CcSEcCtD
Rasagiline—Abdominal pain—Carmustine—lymphatic system cancer	0.000609	0.000696	CcSEcCtD
Rasagiline—Body temperature increased—Carmustine—lymphatic system cancer	0.000609	0.000696	CcSEcCtD
Rasagiline—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000602	0.000688	CcSEcCtD
Rasagiline—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00059	0.000675	CcSEcCtD
Rasagiline—Dysuria—Methotrexate—lymphatic system cancer	0.000587	0.000671	CcSEcCtD
Rasagiline—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000586	0.00067	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000583	0.000667	CcSEcCtD
Rasagiline—Body temperature increased—Vincristine—lymphatic system cancer	0.000582	0.000665	CcSEcCtD
Rasagiline—Abdominal pain—Vincristine—lymphatic system cancer	0.000582	0.000665	CcSEcCtD
Rasagiline—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000578	0.000661	CcSEcCtD
Rasagiline—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000573	0.000655	CcSEcCtD
Rasagiline—Urticaria—Mitoxantrone—lymphatic system cancer	0.000569	0.000651	CcSEcCtD
Rasagiline—Hypersensitivity—Carmustine—lymphatic system cancer	0.000568	0.000649	CcSEcCtD
Rasagiline—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000566	0.000647	CcSEcCtD
Rasagiline—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000566	0.000647	CcSEcCtD
Rasagiline—Vomiting—Bleomycin—lymphatic system cancer	0.000561	0.000642	CcSEcCtD
Rasagiline—Infestation NOS—Methotrexate—lymphatic system cancer	0.00056	0.00064	CcSEcCtD
Rasagiline—Infestation—Methotrexate—lymphatic system cancer	0.00056	0.00064	CcSEcCtD
Rasagiline—Depression—Methotrexate—lymphatic system cancer	0.000558	0.000638	CcSEcCtD
Rasagiline—Rash—Bleomycin—lymphatic system cancer	0.000557	0.000636	CcSEcCtD
Rasagiline—Dermatitis—Bleomycin—lymphatic system cancer	0.000556	0.000636	CcSEcCtD
Rasagiline—Asthenia—Carmustine—lymphatic system cancer	0.000553	0.000632	CcSEcCtD
Rasagiline—Stomatitis—Methotrexate—lymphatic system cancer	0.000546	0.000624	CcSEcCtD
Rasagiline—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000544	0.000622	CcSEcCtD
Rasagiline—Hypersensitivity—Vincristine—lymphatic system cancer	0.000542	0.00062	CcSEcCtD
Rasagiline—Sweating—Methotrexate—lymphatic system cancer	0.000537	0.000613	CcSEcCtD
Rasagiline—Haematuria—Methotrexate—lymphatic system cancer	0.000534	0.00061	CcSEcCtD
Rasagiline—Epistaxis—Methotrexate—lymphatic system cancer	0.000528	0.000604	CcSEcCtD
Rasagiline—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000528	0.000603	CcSEcCtD
Rasagiline—Asthenia—Vincristine—lymphatic system cancer	0.000528	0.000603	CcSEcCtD
Rasagiline—Diarrhoea—Carmustine—lymphatic system cancer	0.000527	0.000603	CcSEcCtD
Rasagiline—Nausea—Bleomycin—lymphatic system cancer	0.000524	0.0006	CcSEcCtD
Rasagiline—Asthenia—Mitoxantrone—lymphatic system cancer	0.000514	0.000588	CcSEcCtD
Rasagiline—Dizziness—Carmustine—lymphatic system cancer	0.00051	0.000583	CcSEcCtD
Rasagiline—Haemoglobin—Methotrexate—lymphatic system cancer	0.000505	0.000577	CcSEcCtD
Rasagiline—Diarrhoea—Vincristine—lymphatic system cancer	0.000503	0.000575	CcSEcCtD
Rasagiline—Haemorrhage—Methotrexate—lymphatic system cancer	0.000502	0.000574	CcSEcCtD
Rasagiline—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000496	0.000567	CcSEcCtD
Rasagiline—Urethral disorder—Methotrexate—lymphatic system cancer	0.000493	0.000563	CcSEcCtD
Rasagiline—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00049	0.00056	CcSEcCtD
Rasagiline—Vomiting—Carmustine—lymphatic system cancer	0.00049	0.00056	CcSEcCtD
Rasagiline—Dizziness—Vincristine—lymphatic system cancer	0.000486	0.000556	CcSEcCtD
Rasagiline—Rash—Carmustine—lymphatic system cancer	0.000486	0.000555	CcSEcCtD
Rasagiline—Dermatitis—Carmustine—lymphatic system cancer	0.000485	0.000555	CcSEcCtD
Rasagiline—Headache—Carmustine—lymphatic system cancer	0.000483	0.000552	CcSEcCtD
Rasagiline—Eye disorder—Methotrexate—lymphatic system cancer	0.00047	0.000537	CcSEcCtD
Rasagiline—Vomiting—Vincristine—lymphatic system cancer	0.000468	0.000535	CcSEcCtD
Rasagiline—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000466	0.000533	CcSEcCtD
Rasagiline—Rash—Vincristine—lymphatic system cancer	0.000464	0.00053	CcSEcCtD
Rasagiline—Dermatitis—Vincristine—lymphatic system cancer	0.000463	0.00053	CcSEcCtD
Rasagiline—Headache—Vincristine—lymphatic system cancer	0.000461	0.000527	CcSEcCtD
Rasagiline—Nausea—Carmustine—lymphatic system cancer	0.000458	0.000523	CcSEcCtD
Rasagiline—Angiopathy—Methotrexate—lymphatic system cancer	0.000456	0.000521	CcSEcCtD
Rasagiline—Vomiting—Mitoxantrone—lymphatic system cancer	0.000456	0.000521	CcSEcCtD
Rasagiline—Immune system disorder—Methotrexate—lymphatic system cancer	0.000454	0.000519	CcSEcCtD
Rasagiline—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000453	0.000518	CcSEcCtD
Rasagiline—Rash—Mitoxantrone—lymphatic system cancer	0.000452	0.000516	CcSEcCtD
Rasagiline—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000451	0.000516	CcSEcCtD
Rasagiline—Chills—Methotrexate—lymphatic system cancer	0.000451	0.000515	CcSEcCtD
Rasagiline—Headache—Mitoxantrone—lymphatic system cancer	0.000449	0.000513	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—lymphatic system cancer	0.000444	0.000508	CcSEcCtD
Rasagiline—Mental disorder—Methotrexate—lymphatic system cancer	0.00044	0.000503	CcSEcCtD
Rasagiline—Malnutrition—Methotrexate—lymphatic system cancer	0.000437	0.0005	CcSEcCtD
Rasagiline—Nausea—Vincristine—lymphatic system cancer	0.000437	0.0005	CcSEcCtD
Rasagiline—Dysgeusia—Methotrexate—lymphatic system cancer	0.000428	0.00049	CcSEcCtD
Rasagiline—Nausea—Mitoxantrone—lymphatic system cancer	0.000426	0.000487	CcSEcCtD
Rasagiline—Back pain—Methotrexate—lymphatic system cancer	0.000423	0.000484	CcSEcCtD
Rasagiline—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000406	0.000464	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—lymphatic system cancer	0.000404	0.000462	CcSEcCtD
Rasagiline—Malaise—Methotrexate—lymphatic system cancer	0.000394	0.000451	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—lymphatic system cancer	0.000393	0.000449	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—lymphatic system cancer	0.000392	0.000448	CcSEcCtD
Rasagiline—Cough—Methotrexate—lymphatic system cancer	0.000382	0.000436	CcSEcCtD
Rasagiline—Convulsion—Methotrexate—lymphatic system cancer	0.000379	0.000433	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—lymphatic system cancer	0.000372	0.000426	CcSEcCtD
Rasagiline—Chest pain—Methotrexate—lymphatic system cancer	0.000372	0.000426	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00037	0.000423	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—lymphatic system cancer	0.000368	0.000421	CcSEcCtD
Rasagiline—Confusional state—Methotrexate—lymphatic system cancer	0.00036	0.000411	CcSEcCtD
Rasagiline—Infection—Methotrexate—lymphatic system cancer	0.000355	0.000405	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00035	0.0004	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—lymphatic system cancer	0.000347	0.000396	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000345	0.000395	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—lymphatic system cancer	0.00034	0.000389	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—lymphatic system cancer	0.000334	0.000381	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000325	0.000372	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—lymphatic system cancer	0.000323	0.000369	CcSEcCtD
Rasagiline—Paraesthesia—Methotrexate—lymphatic system cancer	0.000321	0.000366	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—lymphatic system cancer	0.000318	0.000364	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—lymphatic system cancer	0.000317	0.000363	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—lymphatic system cancer	0.000314	0.000359	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—lymphatic system cancer	0.00031	0.000355	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000308	0.000352	CcSEcCtD
Rasagiline—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000294	0.000336	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000292	0.000334	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—lymphatic system cancer	0.000284	0.000324	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—lymphatic system cancer	0.000282	0.000323	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—lymphatic system cancer	0.000282	0.000323	CcSEcCtD
Rasagiline—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000263	0.000301	CcSEcCtD
Rasagiline—Asthenia—Methotrexate—lymphatic system cancer	0.000256	0.000293	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—lymphatic system cancer	0.000253	0.000289	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—lymphatic system cancer	0.000244	0.000279	CcSEcCtD
Rasagiline—Dizziness—Methotrexate—lymphatic system cancer	0.000236	0.00027	CcSEcCtD
Rasagiline—Vomiting—Methotrexate—lymphatic system cancer	0.000227	0.000259	CcSEcCtD
Rasagiline—Rash—Methotrexate—lymphatic system cancer	0.000225	0.000257	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—lymphatic system cancer	0.000225	0.000257	CcSEcCtD
Rasagiline—Headache—Methotrexate—lymphatic system cancer	0.000224	0.000256	CcSEcCtD
Rasagiline—Nausea—Methotrexate—lymphatic system cancer	0.000212	0.000242	CcSEcCtD
